


Speakers



Boris Kantor, Ph.D.

Assistant Professor and
Viral Vector Core Director
Duke University



**Johannes C. M.
van der Loo, Ph.D.**

Director, Clinical Vector
Core, The Children's
Hospital of Philadelphia



**Miguel
Dominguez, M.S.**

Global Distribution Manager
Mirus Bio LLC

**Tuesday
November 7, 2017**

**11:00 am ET
8:00 am PT
17:00 CET**

DURATION: 60 minutes
COST: Complimentary



Addressing the Challenges of Therapeutic Vector Development

Free Registration!

www.GENengnews.com/ViralVector

The dynamic landscape of molecular biology has bolstered gene-therapy endeavors, underscoring their true therapeutic potential in recent years. Investigators have come to realize that gene therapy is only as good as the vectors employed to deliver the molecular payload. For many researchers, vector development is a common yet laborious practice, often without much thought to how the process may affect more important downstream applications. In this GEN webinar, we will discuss factors that are critical for viral vector development from the analytical scale to larger clinical-scale manufacturing modalities. Drawing attention to these parameters will ultimately lead to better downstream transductions for gene expression and knockdown or genome editing.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.

Who Should Attend

- Molecular biologists
- Researchers interested in gene therapies
- Virologists
- Translational researchers
- Clinical investigators
- Cell biologists

You Will Learn

- The challenges facing researchers when developing viral vectors for use as clinical therapeutics
- Methodologies to streamline vector development strategies
- Insights into the future of viral vectors for gene therapy

Produced with support from

